Funding Overview
Vivacta Biotechnology, a San Diego-based immunotherapy company, raised $50 million in Series A funding to advance its in vivo CAR-T cell engineering platform. The funding will support IND-enabling studies and initial clinical trials for lead cancer indications.
The round was led by Pioneer Fund with participation from Bison Capital, BlueOak Capital, and founding investor Y Combinator. The financing values the company at approximately $200 million post-money, recognizing significant potential for the platform technology.
This substantial Series A financing reflects investor confidence in Vivacta's unique approach to solving the fundamental limitations of current CAR-T therapy—expensive ex vivo manufacturing, supply chain complexity, and treatment delays. The funding will enable the company to advance its lead candidate into clinical trials and demonstrate the platform's potential.
The CAR-T Challenge
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, achieving remarkable responses in hematologic malignancies that had proven resistant to conventional therapies. However, current approaches require expensive, complex ex vivo manufacturing—taking patient T cells, engineering them in a specialized laboratory, and reinfusing them after extensive quality testing.
This autologous manufacturing process costs $100,000-$500,000 per patient, requires treatment at specialized centers, and creates substantial supply chain challenges. Each patient's cells must be collected, transported, engineered, tested, and returned—a multi-week process that delays treatment initiation.
Additionally, many patients eligible for CAR-T therapy are too sick to wait for the 2-4 week manufacturing process, and some cannot provide sufficient T cells for engineering due to prior treatments or disease-related lymphopenia. This leaves significant unmet need even for approved indications.
Allogeneic "off-the-shelf" approaches using donor cells address some limitations but introduce graft-versus-host risk and require immunosuppression. The field has increasingly focused on approaches to engineer T cells in vivo—directly within the patient's body—without external manufacturing.
In Vivo CAR-T Platform
Vivacta has developed proprietary technology for in vivo T-cell engineering using lipid nanoparticle delivery. The approach uses specially designed nanoparticles that selectively target T cells and deliver CAR-encoding nucleic acids directly, enabling engineering within the patient's own immune system.
Key advantages include eliminating ex vivo manufacturing (significantly reduced costs), patient-matched cells (no donor matching required), rapid treatment initiation (days rather than weeks), and scalable manufacturing (nanoparticle production is inherently scalable compared to cell therapy).
The platform was developed through decade-long research at UC San Diego, with foundational work on T-cell targeting lipids published in leading journals including Nature Nanotechnology and ACS Nano. The company has exclusively licensed relevant intellectual property.
The technology builds on advances in lipid nanoparticle delivery demonstrated successful for mRNA vaccines, extending these approaches to enable functional gene delivery to immune cells. This represents a significant extension of proven delivery technology.
Technology Platform
The Vivacta platform integrates several key technological components:
- T-Cell Targeting Lipids: Proprietary lipid formulations engineered to selectively deliver cargo to T cells with minimal off-target delivery
- CAR-Encoding Nucleic Acids: Genetic instructions for CAR expression delivered to enable persistent antigen receptor expression
- Conditioning Enhancement: Small molecules that improve T-cell engineering efficiency and ensure adequate engraftment
- Manufacturing Process: Scalable nanoparticle production process suitable for commercial scale
Lead Programs
The company's lead programs target hematologic malignancies where CAR-T therapy has demonstrated significant efficacy:
- VCT-101 (CD19): For B-cell lymphoma, IND-enabling studies ongoing with IND filing planned for 2027
- VCT-201 (BCMA): For multiple myeloma, preclinical with IND-enabling studies planned for 2028
- VCT-301 (CD20): For chronic lymphocytic leukemia, discovery stage
Preclinical Data
Vivacta has demonstrated in vivo engineering in multiple preclinical models. In mouse models, a single intravenous administration of nanoparticles resulted in CAR expression on more than 50% of circulating T cells within 7 days, with expression persisting for the duration of observation.
The engineered T cells demonstrated anti-tumor activity comparable to conventionally manufactured CAR-T cells in lymphoma models, with complete tumor regressions observed in a majority of treated animals. Survival was significantly improved compared to untreated controls.
Toxicology studies in non-human primates showed acceptable safety profiles with no cytokine release syndrome or neurotoxicity at therapeutic doses. The company has completed GLP toxicology studies supporting advancement to clinical trials.
Pharmacokinetic analysis showed rapid distribution to lymphoid tissues with minimal off-target accumulation, supporting the targeted delivery approach.
Leadership
Founded by Sarah Chen, PhD, and Marcus Williams, MD, PhD, who met during research at UC San Diego. Sarah Chen serves as CEO, bringing 15 years of biotech experience including leadership roles at Gilead Sciences and CRISPR Therapeutics.
Marcus Williams serves as Chief Medical Officer, a board-certified hematologist-oncologist with extensive clinical trial experience in cell therapy. Prior to Vivacta, he served as medical director for CAR-T programs at a major academic medical center.
The team has grown to 35 employees across research, clinical, and operational functions. Key hires include experienced cell therapy developers from Kite Pharma, Juno Therapeutics, and other leading companies.
Funding Allocation
The $50 million Series A will support IND-enabling studies for VCT-101, initial clinical trial execution, and continued platform development. Funding will also support expanding manufacturing capabilities and regulatory interactions with FDA to prepare for global clinical trials.
The company plans to establish clinical trial sites at leading US cancer centers with extensive experience in CAR-T therapy administration and patient management.
Business Model
Vivacta plans to develop the platform through initial clinical validation, with the option to pursue partnerships with major pharmaceutical companies for broader commercialization. The in vivo approach could significantly reduce costs and expand patient access to CAR-T therapy.
Target pricing for in vivo CAR-T therapy could be 50-70% lower than current ex vivo approaches, potentially enabling broader insurance coverage and patient access. The company estimates potential cost savings of over $100,000 per patient.
Market Opportunity
The CAR-T market exceeds $15 billion globally and continues growing as new indications receive approval. Current approved CAR-T therapies address hematologic malignancies including lymphoma, leukemia, and multiple myeloma, with significant ongoing development for solid tumors.
Vivacta's in vivo approach could expand the addressable market by reducing costs, enabling treatment of patients currently ineligible for CAR-T therapy, and expanding treatment to community hospitals without cell therapy infrastructure.
Related companies advancing cell therapy including Cellicir, which is boosting immune cell therapy using mRNA, and Windus Therapeutics, which is developing advanced CRISPR delivery for gene editing, demonstrate continued investment in cell therapy innovation.
Competitive Landscape
Current competition comes from established ex vivo CAR-T therapies (Kite/Juno, Novartis, BMS), allogeneic approaches (allogeneic therapies in development), and in vivo approaches (Vivacta and several academic groups). Vivacta's advantage is clinical stage development with demonstrated in vivo engineering.
Looking Ahead
Vivacta is positioned to transform CAR-T therapy through in vivo engineering. Success depends on clinical validation showing comparable efficacy to conventional approaches with improved safety, reduced costs, and expanded accessibility.
The company plans to pursue rapid clinical development with parallel enrollment in multiple indications following initial clinical proof-of-concept.